SAREUM HOLDINGS PLC

Management Reports • Sep 15, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9499Y

Sareum Holdings PLC

15 September 2015

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that the U.S. Patent and Trademark Office and the European Patent Office have issued notifications that patents will be granted for inventions associated with Sareum's Aurora+FLT3 Kinase Inhibitor Programme.

These patents* describe compounds that inhibit the activity of Aurora and FLT3 kinase enzymes and the medical use of these compounds, particularly in the treatment of cancer. The granting of these patents means that Sareum will have approved patent protection in the US and Europe for its Aurora+FLT3 inhibitor programme. The US patent will be granted on 15 September and the European patent will be granted, subject to the completion of certain formalities, shortly after 25 September. The Company expects that similar patents will be granted in other major markets, including Japan and China, in due course.

Sareum's Aurora+FLT3 inhibitor programme targets acute myeloid leukaemia (AML) and other leukaemias and lymphomas. In disease models of AML, the preclinical development candidate molecule demonstrates greater than 98% tumour inhibition. Preclinical development studies to obtain approval for human clinical trials are being undertaken in collaboration with, and funded by, Hebei Medical University Biomedical Engineering Center in China.

* Patent Nos. US 9,133,180 & EP2812328

Sareum's CSO, Dr John Reader, commented: "These notifications of patent grants for Sareum in the USA and Europe demonstrate the strength of the intellectual property protecting our Aurora+FLT3 programme, and enhance our negotiating position with potential licensing partners".

For further information:

Sareum Holdings plc
Tim Mitchell	01223 497 700
WH Ireland Limited (Nominated Adviser and Co-Broker)
Chris Fielding / Nick Prowting	020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce / William Lynne	020 3764 2341
The Communications Portfolio (Media enquiries)
Ariane Comstive [email protected]	07785 922 354

Notes for editors:

Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, for licensing to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and autoimmune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the symbol SAR. For further information, please visit www.sareum.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLIFVAAFISLIE